BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

This study is testing a new CAR-T cell therapy (an immune cell treatment engineered to target a protein called BAFF-R) for people with relapsed or treatment-resistant B-cell non-Hodgkin lymphoma. This therapy may be an option for patients who have stopped responding to standard or even prior CAR-T treatments. **You may be eligible if...** - You are 18 or older - You have confirmed B-cell non-Hodgkin lymphoma (including large B-cell, mantle cell, or follicular/marginal zone lymphoma) - Your lymphoma expresses the BAFF-R protein - Your cancer has returned or is no longer responding to standard therapy - Your organ function (heart, liver, kidneys, blood counts) is at acceptable levels - You are HIV negative or have well-controlled HIV **You may NOT be eligible if...** - You have had an allogeneic (donor) stem cell transplant - You have active cancer in the brain or spinal cord - You have serious heart disease (recent heart attack, stroke, or severe heart failure) - You have a seizure disorder or prior optic neuritis - You are pregnant or breastfeeding - You have an active autoimmune disease requiring immunosuppressive treatment Talk to your doctor to see if this trial is right for you.